Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 14, 2018 | June 15, 2018 |
| Annexon, Inc.ANNX · Entity 5011 | Director | June 11, 2026 | June 15, 2026 |
| AxonPrime Infrastructure Acquisition Corp[APMI] · Entity 136141 | Director | August 12, 2021 | August 13, 2021 |
| IMMUNIC, INC.VTL · Entity 6306 | Director · 10% owner | September 13, 2018 | September 18, 2018 |
| Rein Therapeutics, Inc.ALRN · Entity 7071 | Director · See Remarks | January 08, 2021 | January 08, 2021 |
| Whitehawk Therapeutics, Inc.ARPO · Entity 6074 | Director · 10% owner | June 18, 2019 | June 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 14, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2028-06-14 | Direct | 12,500 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 12,500 · Balance 12,500 F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company.
Annexon, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11 | Direct | 65,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.
AxonPrime Infrastructure Acquisition Corp
Report date August 12, 2021 · Filed August 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-08-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-257777) under the heading "Description of Securities-Founder Shares," the shares of Class B Common Stock will automatically convert into shares of Class A Common Stock at the time of the initial business combination of the Issuer on a one-for-one basis, subject to certain adjustments, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-257777) under the heading "Description of Securities-Founder Shares," the shares of Class B Common Stock will automatically convert into shares of Class A Common Stock at the time of the initial business combination of the Issuer on a one-for-one basis, subject to certain adjustments, and have no expiration date.
IMMUNIC, INC.
Report date September 13, 2018 · Filed September 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 7,492,277 |
Reported balance
After 2018-09-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-09-13 · Sale · Disposed 3,890,000 · Balance 7,492,277 F1: The amount in Column 4 includes (a) 1,436,391 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,001,131 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,452,478 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.41 to $0.598. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (2) to this Form 4. F3: The amount in Column 5 includes (a) 2,766,539 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,928,216 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,797,522 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 7,044,777 |
Reported balance
After 2018-09-14 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-09-14 · Sale · Disposed 447,500 · Balance 7,044,777 F4: The amount in Column 4 includes (a) 165,240 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 115,169 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c)167,091 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (4), except to the extent of his pecuniary interest. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.40. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (5) to this Form 4. F6: The amount in Column 5 includes (a) 2,601,299 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (6), except to the extent of his pecuniary interest. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2018-09-17 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-09-17 · Sale · Disposed 7,044,777 · Balance 0 F7: The amount in Column 4 includes (a) 2,601,299 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (7), except to the extent of his pecuniary interest. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.3646. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (8) to this Form 4. F9: All shares previously held by (a) the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee, (b) by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager, and (c) Satter Medical Technology Partners, L.P. for which the Reporting Person had sole voting and dispositive power over all such shares, have been disposed of as of the date of the filing of this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The amount in Column 4 includes (a) 1,436,391 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,001,131 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,452,478 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.41 to $0.598. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (2) to this Form 4.
F3: The amount in Column 5 includes (a) 2,766,539 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,928,216 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,797,522 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest.
F4: The amount in Column 4 includes (a) 165,240 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 115,169 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c)167,091 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (4), except to the extent of his pecuniary interest.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.40. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (5) to this Form 4.
F6: The amount in Column 5 includes (a) 2,601,299 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (6), except to the extent of his pecuniary interest.
F7: The amount in Column 4 includes (a) 2,601,299 shares sold by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,813,047 shares sold by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 2,630,431 shares sold by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (7), except to the extent of his pecuniary interest.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.3646. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (8) to this Form 4.
F9: All shares previously held by (a) the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee, (b) by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager, and (c) Satter Medical Technology Partners, L.P. for which the Reporting Person had sole voting and dispositive power over all such shares, have been disposed of as of the date of the filing of this Form 4.
Rein Therapeutics, Inc.
Report date January 08, 2021 · Filed January 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 16,609,449 |
Reported balance
After 2021-01-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-01-08 · Purchase · Acquired 9,000,000 · Balance 16,609,449 F1: Reflects shares that were purchased from the Issuer on January 8, 2021 in a registered direct offering pursuant to a Securities Purchase Agreement, dated January 6, 2021. The amount in Column 4 includes (a) 863,636 shares purchased by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 863,636 shares purchased by various trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (c) 7,272,728 shares purchased by Satter Medical Technology Partners, L.P. ("SMTP") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest therein. F2: The amount in Column 5 includes (a) 1,025,076 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,231,044 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares that were purchased from the Issuer on January 8, 2021 in a registered direct offering pursuant to a Securities Purchase Agreement, dated January 6, 2021. The amount in Column 4 includes (a) 863,636 shares purchased by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 863,636 shares purchased by various trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (c) 7,272,728 shares purchased by Satter Medical Technology Partners, L.P. ("SMTP") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest therein.
F2: The amount in Column 5 includes (a) 1,025,076 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,231,044 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein.
Whitehawk Therapeutics, Inc.
Report date June 18, 2019 · Filed June 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2029-06-18 | Direct | 21,400 |
Reported balance
After 2019-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-18 · Grant · Acquired 21,400 · Balance 21,400 F1: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 20:15 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001315797-26-000002 · form4-06152026_040611.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| May 28, 2026 Filed May 29, 2026 21:21 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 613,497 | $5.41 | $3,319,018.77 |
DisclosureSEC source: 0001315797-26-000001 · form4-05292026_090557.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 10,342,134 F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: As of May 28, 2026, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 8,387,156 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein. Read SEC document |
| November 21, 2025 Filed Nov 22, 2025 02:52 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 422,613 | $4.28 | $1,808,783.64 |
DisclosureSEC source: 0001315797-25-000007 · form4-11222025_021158.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 9,728,637 F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F4 · price: This transaction was executed in multiple trades in prices ranging from $4.165 to $4.415, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F3 · ownership.nature: As of November 21, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 7,773,659 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 02:52 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 400,000 | $4.48 | $1,792,000.00 |
DisclosureSEC source: 0001315797-25-000007 · form4-11222025_021158.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 9,306,024 F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F2 · price: This transaction was executed in multiple trades in prices ranging from $4.25 to $5.065, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F3 · ownership.nature: As of November 21, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 7,773,659 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 02:00 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 500,000 | $3.94 | $1,970,000.00 |
DisclosureSEC source: 0001315797-25-000006 · form4-11192025_091101.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,906,024 F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F5 · price: This transaction was executed in multiple trades in prices ranging from $3.57 to $4.19, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F3 · ownership.nature: As of November 19, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 6,951,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 02:00 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 500,000 | $3.18 | $1,590,000.00 |
DisclosureSEC source: 0001315797-25-000006 · form4-11192025_091101.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,406,024 F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F4 · price: This transaction was executed in multiple trades in prices ranging from $3.01 to $3.285, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F3 · ownership.nature: As of November 19, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 6,951,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 02:00 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 500,000 | $2.99 | $1,495,000.00 |
DisclosureSEC source: 0001315797-25-000006 · form4-11192025_091101.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,906,024 F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical"). The Reporting Person has sole voting and dispositive power over the shares held by Alerce Medical. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.695 to $3.115, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. F3 · ownership.nature: As of November 19, 2025, includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and entities for which the Reporting Person serves as trustee, investment advisor or manager, as applicable, and, in each such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 6,951,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest therein. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:27 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001415889-25-016267 · form4-06092025_080602.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 01:44 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 44,000 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0001415889-24-016106 · form4-06082024_010634.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2024 or (ii) the next Annual Meeting following June 5, 2024, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 21:30 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 350,000 | $2.88 | $1,008,000.00 |
DisclosureSEC source: 0001209191-23-059911 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,406,024 F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 5,451,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power of all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:52 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001610717-23-000152 · form4.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 8, 2023 or (ii) the next Annual Meeting following June 8, 2023, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:31 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 2,647,058 | $6.80 | $17,999,994.40 |
DisclosureSEC source: 0001567619-23-002932 · doc1.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 7,056,024 F1 · shares: All shares were purchased by Alerce Medical Technology Partners, L.P. ("Alerce Medical") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 5,101,046 shares that are held by Alerce Medical for which the Reporting Person has sole voting and dispositive power of all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest. Read SEC document |
| July 07, 2022 Filed Jul 12, 2022 00:42 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseWarrants (Right to Buy) · Derivative | 613,497 | $0.13 Strike: $5.81 | $76,687.13 |
DisclosureSEC source: 0001567619-22-013890 · doc1.xml · derivative · entry 2 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 613,497 Underlying: Common Stock · 613,497 shares Expires 2025-06-30 F3 · ownership.nature: The warrants are held by SMTP II for which the Reporting Person has sole voting and dispositive power of all such warrants. The Reporting Person disclaims beneficial ownership of all the warrants, except to the extent of his pecuniary interest. Read SEC document |
| July 07, 2022 Filed Jul 12, 2022 00:42 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 2,453,988 | $3.84 | $9,423,313.92 |
DisclosureSEC source: 0001567619-22-013890 · doc1.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,408,966 F1 · shares: Reflects shares that were purchased from the Issuer on July 7, 2022 in a private offering pursuant to a Securities Purchase Agreement, dated July 7, 2022. The shares were purchased by Satter Medical Technology Partners II, L.P. ("SMTP II") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: Includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, (c) 1,147,738 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares and (d) 2,453,988 shares that are held by SMTP II for which the Reporting Person has sole voting and dispositive power of all such shares. The Reporting Person disclaims beneficial ownership of all shares included under (b), (c) and (d) of this footnote, except to the extent of his pecuniary interest. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:41 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001567619-22-012779 · doc1.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 9, 2022 or (ii) the next Annual Meeting following June 9, 2022, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:14 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001567619-21-011723 · doc1.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 2, 2021 or (ii) the next Annual Meeting following June 2, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| January 08, 2021 Filed Jan 8, 2021 21:15 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 9,000,000 | $1.10 | $9,900,000.00 |
DisclosureSEC source: 0000899243-21-001163 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 16,609,449 F1 · shares: Reflects shares that were purchased from the Issuer on January 8, 2021 in a registered direct offering pursuant to a Securities Purchase Agreement, dated January 6, 2021. The amount in Column 4 includes (a) 863,636 shares purchased by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 863,636 shares purchased by various trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (c) 7,272,728 shares purchased by Satter Medical Technology Partners, L.P. ("SMTP") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (1), except to the extent of his pecuniary interest therein. F2 · balance_after: The amount in Column 5 includes (a) 1,025,076 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,231,044 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein. F2 · ownership.nature: The amount in Column 5 includes (a) 1,025,076 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,231,044 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 20:17 UTC | Annexon, Inc. ANNX · Entity 5011 | ConversionSeries D Preferred Stock · Derivative | 2,812,543 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-013817 · doc1.xml · derivative · entry 6 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 319,244 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.underlying_shares: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held by Satter Medical Technology Partners, L.P. ("SMTP"), for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in this footnote (4), except to the extent of his pecuniary interest. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 20:17 UTC | Annexon, Inc. ANNX · Entity 5011 | ConversionSeries C Preferred Stock · Derivative | 5,537,036 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-013817 · doc1.xml · derivative · entry 5 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 628,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.underlying_shares: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F4 · ownership.nature: Represents shares held by Satter Medical Technology Partners, L.P. ("SMTP"), for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in this footnote (4), except to the extent of his pecuniary interest. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 20:17 UTC | Annexon, Inc. ANNX · Entity 5011 | ConversionSeries B Preferred Stock · Derivative | 4,016,573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-013817 · doc1.xml · derivative · entry 4 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 455,909 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.underlying_shares: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F3 · ownership.nature: The amount in Column 5 includes (a) 1,162,022 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares and (b) 2,854,551 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clause (b) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 20:17 UTC | Annexon, Inc. ANNX · Entity 5011 | ConversionSeries A-1 Preferred Stock · Derivative | 3,095,238 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-013817 · doc1.xml · derivative · entry 3 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 351,331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.underlying_shares: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The amount in Column 5 includes (a) 952,381 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares and (b) 2,142,857 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clause (b) of this footnote (2), except to the extent of his pecuniary interest. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 20:17 UTC | Annexon, Inc. ANNX · Entity 5011 | PurchaseCommon Stock | 200,000 | $17.00 | $3,400,000.00 |
DisclosureSEC source: 0001567619-20-013817 · doc1.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,954,978 F6 · shares: Represents shares purchased by SMTP in connection with the Issuer's initial public offering. These shares of Common Stock were purchased at the public offering price of $17.00 per share. F7 · ownership.nature: The amount in Column 5 includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 1,147,738 shares that are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (7), except to the extent of his pecuniary interest. Read SEC document |
| July 28, 2020 Filed Jul 28, 2020 20:17 UTC | Annexon, Inc. ANNX · Entity 5011 | ConversionCommon Stock | 1,754,978 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-013817 · doc1.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,754,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · price: The shares of Series A-1, Series B, Series C and Series D Preferred Stock were automatically converted on a 1-for-8.81 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F5 · ownership.nature: The amount in Column 5 includes (a) 240,000 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 567,240 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) 947,738 shares that are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (5), except to the extent of his pecuniary interest. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 00:22 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 3,700,000 | $1.10 | $4,070,000.00 |
DisclosureSEC source: 0000899243-20-015868 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,609,449 F1 · shares: Reflects shares that were purchased directly from the underwriter in an underwritten public offering conducted by the Issuer. The amount in Column 4 includes (a) 350,742 shares purchased by various trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares and (b) 3,349,258 shares purchased by Satter Medical Technology Partners, L.P. ("SMTP") for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (a) and (b) of this footnote (1), except to the extent of his pecuniary interest. F2 · balance_after: The amount in Column 5 includes (a) 161,440 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 367,408 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein. F2 · ownership.nature: The amount in Column 5 includes (a) 161,440 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 367,408 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by SMTP for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (2), except to the extent of his pecuniary interest therein. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 21:26 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-19-017440 · doc4.xml · derivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2029-06-18 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 23,818 | $2.45 | $58,442.23 |
DisclosureSEC source: 0000899243-19-000999 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,621,835 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.36 to $2.52. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.39 | $47,876.00 |
DisclosureSEC source: 0000899243-19-000999 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,598,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.34 to $2.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| January 08, 2019 Filed Jan 11, 2019 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.20 | $43,972.00 |
DisclosureSEC source: 0000899243-19-000999 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,578,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.065 to $2.44. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.18 | $43,558.00 |
DisclosureSEC source: 0000899243-19-000701 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,558,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.075 to $2.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.12 | $42,396.00 |
DisclosureSEC source: 0000899243-19-000701 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,538,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.10 to $2.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.08 | $41,508.00 |
DisclosureSEC source: 0000899243-19-000701 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,518,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.96 to $2.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 02:01 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.94 | $38,838.00 |
DisclosureSEC source: 0000899243-19-000196 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,498,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.845 to $2.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 02:01 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.75 | $34,900.00 |
DisclosureSEC source: 0000899243-19-000196 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,478,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.71 to $1.76. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 28, 2018 Filed Jan 3, 2019 02:01 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.72 | $34,372.00 |
DisclosureSEC source: 0000899243-19-000196 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,458,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.655 to $1.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 00:13 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.67 | $33,410.00 |
DisclosureSEC source: 0000899243-18-031908 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,438,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.63 to $1.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 00:13 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.69 | $33,854.00 |
DisclosureSEC source: 0000899243-18-031908 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,418,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.58 to $1.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 21, 2018 Filed Dec 28, 2018 00:13 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.84 | $36,870.00 |
DisclosureSEC source: 0000899243-18-031908 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,398,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.72 to $2.03. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 00:04 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.85 | $36,984.00 |
DisclosureSEC source: 0000899243-18-031493 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,378,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.80 to $1.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 00:04 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.92 | $38,384.00 |
DisclosureSEC source: 0000899243-18-031493 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,358,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.81 to $2.06. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 00:04 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.99 | $39,856.00 |
DisclosureSEC source: 0000899243-18-031493 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,338,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $2.06. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 14, 2018 Filed Dec 15, 2018 01:55 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.00 | $40,094.00 |
DisclosureSEC source: 0000899243-18-031136 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,318,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.94 to $2.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 13, 2018 Filed Dec 15, 2018 01:55 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.02 | $40,308.00 |
DisclosureSEC source: 0000899243-18-031136 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,298,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.99 to $2.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 01:55 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.05 | $40,938.00 |
DisclosureSEC source: 0000899243-18-031136 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,278,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.00 to $2.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 01:52 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.09 | $41,846.00 |
DisclosureSEC source: 0000899243-18-030684 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,258,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.15. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 01:52 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.13 | $42,608.00 |
DisclosureSEC source: 0000899243-18-030684 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,238,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.08 to $2.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 01:52 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.14 | $42,788.00 |
DisclosureSEC source: 0000899243-18-030684 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,218,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.06 to $2.205. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 06, 2018 Filed Dec 7, 2018 01:54 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.18 | $43,584.00 |
DisclosureSEC source: 0000899243-18-030326 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,198,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.07 to $2.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 04, 2018 Filed Dec 7, 2018 01:54 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $2.10 | $41,994.00 |
DisclosureSEC source: 0000899243-18-030326 · doc4.xml · nonDerivative · entry 2 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,178,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.99 to $2.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| December 03, 2018 Filed Dec 7, 2018 01:54 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.99 | $39,774.00 |
DisclosureSEC source: 0000899243-18-030326 · doc4.xml · nonDerivative · entry 1 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,158,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.94 to $2.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
| November 30, 2018 Filed Dec 1, 2018 02:00 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | PurchaseCommon Stock | 20,000 | $1.98 | $39,692.00 |
DisclosureSEC source: 0000899243-18-029916 · doc4.xml · nonDerivative · entry 3 Satter Muneer A · CIK 0001315797 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,138,017 F1 · kind: All shares were purchased by Satter Medical Technology Partners, L.P. F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.85 to $2.09. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F3 · ownership.nature: The amount in Column 5 includes (a) 976,568 shares that are held by the Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares, (b) 1,145,267 shares that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares, and (c) the remaining balance of shares are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares. The Reporting Person disclaims beneficial ownership of all shares included in clauses (b) and (c) of this footnote (3), except to the extent of his pecuniary interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.